CYP19A1 and neoplasm: For those patients with HR-positive tumor, adjuvant endocrine therapy was administered as follows: 68 patients (20.2%) received tamoxifen, 167 patients (49.7%) received aromatase inhibitors (AI), 30 patients (8.9%) received tamoxifen with ovarian function suppression (OFS), and 26 patients (7.7%) received AI with OFS.